From Covid CD12, no. The FDA would want to see at least a 350mg and 700mg arm if not a 350mg, 525mg and 700 mg arm. Because CCR5 levels will be expressed differentially in various diseases they would probably accept RO tests only from leronlimab being used in current HAART patients to match up with the CD02 trial.